Corporate Magazine 2012 - Boehringer Ingelheim

PATIENTS AT CARDIOVASCULAR RISKMost hypertensive patients need morethan just simple blood pressure control.Preserving vascular health and protectingvital end organs is essential too.micardis®, micardisplus® and twynsta®are indicated for the management ofpatients at added risk of cardiovascularevents. These include patients withobesity, diabetes, uncontrolled hypertensionand metabolic syndrome.obesitydiabetesuncontrolledhypertensionmetabolicsyndromeTWYNSTA®/MICAMLO®(telmisartan / amlodipine)Add-on therapy in adult patientswith not adequately controlledblood pressure on amlodipine andreplacement therapy in adult patientsreceiving telmisartan andamlodipine from separate tablets.24-hour control of blood pressure is animportant feature. micardis® aims furtherto protect of end-organs, such asthe brain, heart and kidneys.In 2008, Boehringer Ingelheim completedthe ONTARGET study – a largeand comprehensive clinical trial designedto investigate the direct cardioprotectiveeffect of micardis® beyondthe effects resulting from the loweringof blood pressure.This landmark trial gave clinical prooffor micardis® to prevent stroke, myocardialinfarction (MI) and cardiovasculardeath and led to the indication forcardiovascular prevention beyondblood pressure control.Reducing cardiovascular riskmicardis® is labelled for patientswith hypertension, as well as those atrisk of cardiovascular events. It is anangio tensin receptor blocker (ARB)that is clinically proven to preventstroke, mi and cardiovascular deathand is indicated for cardiovascularprevention beyond blood pressurecontrol.Single-pill combinationsTreatment guidelines recognise that atleast two-thirds of patients need twoantihypertensive agents to effectivelycontrol blood pressure; a figure thatrises to nine out of ten in patients withco-morbidities, such as obesity, diabetesand metabolic syndrome, which are allcardiovascular risk factors. Single-pillcombinations (SPCs) that are effectiveand well-tolerated offer a major benefitfor these patients.MICARDISPLUS®micardisplus® is labelled for hypertensivepatients at risk of cardiovascularevents who need blood pressure controland will benefit from adding a diuretic,e. g. the elderly and where oedema is oftena problem. micardisplus® deliversan efficacy that lasts for a full 24 hours.It contains telmisartan, the only arbwith a cardiovascular prevention indicationand the diuretic hydrochlorothiazide(HCTZ).74Boehringer Ingelheim annual report 2012